대한한방내과학회지 (The Journal of Internal Korean Medicine)

대한한방내과학회 (The Society of Internal Korean Medicine)
권호 표지

식분환(息賁丸) 및 비기환(?氣丸)이 백혈병(白血病) 임파종(淋巴腫) 환자(患者)에서 추출(抽出)한 암세포(癌細胞)에 미치는 항암(抗癌) 효과(效果)

Antitumor Effects of Sigbunhwan and Bigihwan on Tumor Cells derived from Leukemia and Lymphoma Patients

  • Kang, Dae-Geun (DEPT. of oriental Medicine Graduate School Won Kwang University) ;
  • Kang, Byung-Ki (DEPT. of oriental Medicine Graduate School Won Kwang University)
  • 발행 : 1991.01.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Attempts were made to see the antitumor effects of Sigbunhwan widely used in Oh-jug(五積) employing tumor cells Lines such as K562 derived from erythroleukemia, Raji from lympoma and MO-4 from blastogenic tumor. Different concentrations of Sigbunhwan and combined therapy of Sigbunhwan and Bigihwan were treated to those tumor cells lines and then live cells were counted by Trypan blue assay and $^{3}H-Thymidine$ uptake assay. The results obtained were as follows. 1. $^{3}H-Thymidine$ uptake of various tumor cells lines when treated with high concentrations of Sigbunhwan for 48hours showed that the rate of DNA synthesis decreased 76% to 90% by the treatment of 1% Sigbunhwan but this inhibition was rather decreased when Sigbunhwan concentration was increased to 10, 15 and 20%.(Fig 3) 2. When Sigbunhwan was combined with Bigihwan which was also an antitumor drug, the effectiveness of tumor cells dealth was somewhat inceased showing a generally similar pattern to that of Bigihwan alone used.(Fig 4) This combination therapy also showed that higher concentrations of antitumor agent were no more·effective or rather harmful according to the tumor cells lines having different growth rate.(Fig 5,6) 3. The antitumor effects of combined Sigbunhwan and Bigihwan was decreased if the concentrations of this combination therapy was increased to 10 times showing relatively sluggish decrease in K562 and MO-4 but a sharp inhibitory effect in Raji which grows slowly.(Fig 7). 4. When Sigbunhwan was treated at low concentrations, K562 was more inhibited by 0.75% to 1.0% of Sigbunhwan while Raji was more inhibited by 0.25% to 0.5% of that.(Fig 8) 5. When Sigbunhwan was treated together with Bigihwan at low concentrations, the tumor cells death rate was 75% to 89% in Baji, 31% to 95% in MO-4 and 41 to 89% in K562, showing this combination therapy was more effect to Raji derived from lymphoma.(Fig 9) 6. The number of live tumor cells was correlated with optical density of MTT assay when measured with 2% Sigbunhwan treatment to tumor cells lines for 24 hours.(Fig 10) 7. 7 days treatment of 0.25% Sigbunhwan was compared with one day treatment of 1% suggesting long term treatment more effective.(Fig 11)

키워드

참고문헌

  1. 癌溜防治硏究 賈坤
  2. 中醫內學 江蘇新醫學院 中醫內科敎硏組(編)
  3. 肝係內科學 金秉雲(外 8명)
  4. 東醫臨床要覽 金定濟;金賢濟
  5. 靑?決 南采祐
  6. 醫學綱目 v.25 樓全善
  7. 類證治裁 林珮琴
  8. 醫學門徑 徐學山
  9. 治癌中藥及處方 葉銘洪
  10. 巢氏諸病源候論 巢元方
  11. 申氏本草學 申佶求
  12. 韓藥臨床應用 申民敎(外)
  13. 六科準繩 v.2 王肯堂
  14. 外臺秘要 王熹
  15. 醫方集解 汪昻
  16. 中藥藥理與應用 王浴生
  17. 中醫內科辨證學 王顯明
  18. 腫留任證備要 李岩
  19. 中西醫結合治療癌症 張代釗
  20. 儒門事親 v.3 張子和
  21. 腫留的辨證施治 錢伯文
  22. 醫門寶鑑 周命新
  23. 普濟方 朱肅
  24. 丹溪心法附餘 周辰亨
  25. 中醫內科學槪要 中醫學會
  26. 中國 醫學大辭典 中華民國 商務印書館
  27. 三因方 陳無擇
  28. 韓方醫學大典 v.1 陳存仁
  29. 韓方醫學大典 v.2 陳存仁
  30. 韓方醫學大典 v.3 陳存仁
  31. 韓方醫學大典 v.4 陳存仁
  32. 現代中共의 癌治療 洪元植
  33. 東醫寶鑑 許浚
  34. 圓光大學校 碩士學位論文 伏梁丸이 白血病과 肝癌患者에서 抽出한 癌細胞에 미치는 抗癌效果 金剛山
  35. 趙永植 博士 華甲紀念論文集 數種韓藥劑가 制癌制 및 Glucocorticoid의 抗體 生産 抑制作用에 미치는 影響 金光湖(外)
  36. 慶熙韓醫大 論文集 v.2 百消丸 및 加味百消丸이 四鹽化炭素로 因한 白鼠 肝損傷에 미치는 影響에 關하여 文濬典
  37. 慶熙韓醫大 論文集 v.4 肥氣丸이 四鹽化炭素로 因한 白鼠 肝損傷에 미치는 影響 徐政周
  38. 慶熙韓醫大 論文集 v.9 數種의 韓藥物이 癌細胞 感受性에 미치는 影響 任帝訓
  39. Tubular summary of pharmacokinetic parameters relavant to in vitro drug assay : cloning of human tumor stem cells Albert, D.S.;Chen, H.S.G.;Salmon, S.E.(ed.)
  40. Lancet Predicting reponses of human cancer to chemotherapy Beren, Baum M.C.
  41. In vitro assays of chemotherapeutic sensitivity important advances in oncology Carney. D.N.;Winkler, C.F.
  42. Cancer Research v.41 Differential killing efficacy of twenty antitumor drugs on proliferating and non proliferating human tumor cells Drewinko, B.;Patchen, M.L.Y.(et al.)
  43. Cancer Research v.39 A methodological approach to the prediction of anticancer drug effect in humans Durkin, W.J.;Ghanta, V.K.;Balch, C.M.(et al.)
  44. Cancer Research v.48 Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay Alley, M.C.;Scudiero, D.A.;Monks, A.(et al.)
  45. Eur. J. Cancer Clin. Oncol. v.22 Comparison of in vitro activity of cytotoxic drugs towards human canciona and leukemia cell lines Finlay, G.J.;Wilson, W.R.;Baguley, B.C.
  46. Int. J. Radiat . Oncol. Biol. Phys. v.15 no.3 Use of a colorimetric microtiter (MTT) as say in determining the radiosensitivity of cells from murine solid tumors Waserman, T.H.;Twentyman, P.
  47. Oncology Sodium succinate enhances the colorimetric reaction of the in vitro chemosensitivity test : MTT assay Maehara, Y.;Kusumoto, T.;Kusumoto, H.;Anai, H.;Sugimachi, K.
  48. J. Immunol. Methods v.119 no.2 Re-examination and further development of a precise and rapid method for measuring cell growth/cell kill Hansen, M.B.;Nielsen, S.E.;Berg, K.
  49. Cancer Res. v.49 no.16 Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide formazan absorption chemosensitivity determined by a novel tetrazoliumbased assay Plumb, J.A.;Milroy, R.;Kaye, S.B.
  50. Cancer Lett. v.41 no.3 Adapatation of the rapid automated tetrazolium dye base (MTT) assay for chemosensitivity testing in childhood leukemia Pieters, R.;Huismans, D.R.;Leyva, A.;Veerman. A.J.
  51. Cancer Chemother Pharmacol. v.22 no.3 In vitro antitumor activity of mitomycin C derivative(RM-49) and new anticancer antibitis (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay Horiuchi, N.;Nakagawa, K.;Sasaki, Y.;Minato, K.;Fujiwara, Y.;Nezu, K.;Ohe, Y.;Saijo, N.
  52. Cancer Res. v.47 Evaluation of a tetrazolium based semiautomatic Colorimetric assay Carmichael, J.;Degraff, W.G.;Gazdar, A.F.;Minna, J.D.;Mitchell, J.B.
  53. Cancer Res. v.47 Chemosensitivity testing of human coloretal carcinoma cell lines using a tetrazolium based colorimetric assay Park, J.G.;Kramer, B.S.;Steinberg, S.M.
  54. J. Natl. Cancer Inst. v.66 Uses of in vitro tests in predictive cancer chemotherapy Hamburger, A.W.
  55. v.12 The human tumor cloning assay in cancer research and therapy current problems in cacner Hanauske, A.R.;Hanauske. U.;Von Hoff, D.D.
  56. Cancer Research v.83 Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor Heppner, G.H.;Dexter, D.L.;DeNucci, T.(et al.)
  57. Arch. Surg. v.117 Clinical correlatitons with drug sensitivities in the clonogenic assay Mann, B.D.;Kern, D.H.;Giuliano, A.E.(et al.)
  58. Cancer v.52 Predictability of responser to chemotherapy by the clonogenic assay Mann, B.D.;Kristian, Strom F.;Morton, D.L.(et al.)
  59. J. Immunol. Methods v.65 Rapid colrimetric assay for cellular growth and survival : application to proliferation and cytotoxicity assay Mosmarm, T.
  60. Cancer Research v.37 Improved growth of in vitro colonies in human accute leukemia with feeding culture method Park, C.H.;Savin, M.A.;Hoogstraten, B.(et al.)
  61. Cancer Research v.32 Comparison of in vitro methods to determine drug induced cell lethality Roper, P.R.;Drewinko, B.
  62. N. Eng. J. Med. v.298 Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs Salmon, S.E.;Hamburger, A.W.;Soehnlen, B.(et al.)
  63. Br. J. Cancer v.41 Experimental chemotherapy studies : Intercomparison of assays Twentymen, P.R.
  64. Seminars in oncology v.4 In vitro assays in preclinical antineoplastic drug screening Weisenthal, L.M.
  65. Cancer trean Rep. v.6 Clonogenic and non clogenic in vitro Chemosensitivity assays Weisenthal, L.M.;Lippman, M.E.
  66. Cancer treat Rep. v.68 Origins and development of chemotherapy research at the National Cancer Institute Zubod, C.G.
  67. Jpn. Kokai Tokyo koho Jp. Antitumor agents from medical plants Sasaki, S.
  68. Yakuyo Ninjin Sonokenkyu to Shinpo Effects of Ginseng on cancer cell Odajima, Yoshio
  69. J. Exp. Med. Monoclonal cytotoxic T cell lines Baker, P.R.;Gillis, S.;Smith, A.K.
  70. J. Immunol. Methods v.89 Human interleukin 2 : quantitation by a sensitive radioimmunoassay Cardenas, J.M.;Marshall, P.;Henders on B.;Altman, A.
  71. J. Immunol. Methods v.65 Rapid colorimetric assay for cellular growth and survival : application to proliferation cytotoxic assay Mosman, T.
  72. Br. J. Cancer v.48 Failure of high doses of interferon to affect the growth of human carcinoma, melanoma and myeloed leukemia xenografts Clutterbuk, R.D.;Miller, J.L.;Alexander, P.
  73. N. Engl. J. Med. v.311 Treatment of advanced non-Hodgkins lymphoma with recombinant lekocyte A interferon Foon, K.A.;Sherwin, S.A.;Abrams, P.L.;Longo, D.L.;Fer, M.J.;Jaffe, R.S.;Oldham, R.K.
  74. Cancer Chemother Rep v.3 Protocols for screening chemical agent and natural products against animal tumors and other biological system Geran, R.I.;Greemberg, N.H.;Macdonald, M.M.;Schumacher, A.M.;Abbott, B.J.
  75. Ann Intern Med. v.93 Leukocyte interferoninduced tumor regression in human metastatic breast cancer, multiple myeloma and maliganant lymphoma Guttermna, J.U.;Blumenschein, G.R.;Alexanian, R.;Yap, H.Y.;Buzdar, A.U.;Cabanillas, F.;Horrtobagyi, G.N.;Hersh, E.M.;Rasmussen, S.L.;Harmon, M.;Kramer, M.;Pestka, S.
  76. Proc. Natl. Acad Sci. U.S.A. v.69 Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes Lindahl, P.;Leary, P.;Gresser, I.
  77. Cancer Res. v.43 Renal cell carcinoma : Antitumor effects of leukocyte interferon Quesada, J.R.;Swanson, D.A.;Trindade, A.;Gutterman, J.U.
  78. Biken J. v.19 Antitumor effects of interferon on transplated tumors in congeintally athymic nude mice Yokota, Y.;Kishida, T.;Esaki, K.;Kawamata, J.
  79. Yaoxue Tongbao v.19 no.9 Constituents of the essential oil from rhizome of Attactylodes macrocephala produced in pingjiang (China) and their antitumor effects Tang, Defang;Hao, Yohung;Miao, Shulin;Wei, Hua;Wu, Jian